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In view of the rapid preclinical development of cell-based therapies for neurodegenerative disorders, traumatic 
brain injury, and tumors, the safe and efficient delivery and targeting of therapeutic cells to the central nervous 
system is critical for maintaining therapeutic efficacy and safety in the respective disease models. Our previous 
data demonstrated therapeutically efficacious and targeted delivery of mesenchymal stem cells (MSCs) to the 
brain in the rat 6-hydroxydopamine model of Parkinson’s disease (PD). The present study examined delivery 
of bone marrow-derived MSCs, macrophages, and microglia to the brain in a transgenic model of PD [(Thy1)-
h[A30P] aS] and an APP/PS1 model of Alzheimer’s disease (AD) via intranasal application (INA). INA of 
microglia in naive BL/6 mice led to targeted and effective delivery of cells to the brain. Quantitative PCR 
analysis of eGFP DNA showed that the brain contained the highest amount of eGFP-microglia (up to 2.1 × 104) 
after INA of 1 × 106 cells, while the total amount of cells detected in peripheral organs did not exceed 3.4 × 103. 
Seven days after INA, MSCs expressing eGFP were detected in the olfactory bulb (OB), cortex, amygdala, stri-
atum, hippocampus, cerebellum, and brainstem of (Thy1)-h[A30P] aS transgenic mice, showing predominant 
distribution within the OB and brainstem. INA of eGFP-expressing macrophages in 13-month-old APP/PS1 
mice led to delivery of cells to the OB, hippocampus, cortex, and cerebellum. Both MSCs and macrophages 
contained Iba-1-positive population of small microglia-like cells and Iba-1-negative large rounded cells show-
ing either intracellular amyloid b (macrophages in APP/PS1 model) or a-synuclein [MSCs in (Thy1)-h[A30P] 
aS model] immunoreactivity. Here, we show, for the first time, intranasal delivery of cells to the brain of trans-
genic PD and AD mouse models. Additional work is needed to determine the optimal dosage (single treatment 
regimen or repeated administrations) to achieve functional improvement in these mouse models with intranasal 
microglia/macrophages and MSCs. This manuscript is published as part of the International Association of 
Neurorestoratology (IANR) special issue of Cell Transplantation.
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INTRODUCTION
Surgical transplantation of therapeutic cells into the 
brain is a commonly used method of cell application 
for cell-based therapy of neurodegenerative disorders. 
However, this delivery method is associated with sev-
eral issues, such as 1) graft rejection problems resulting 
from immunological responses (43,63); 2) consequences 
of direct tissue trauma, such as inflammation, cerebral 
edema, and reactive gliosis (27,53,57); and 3) difficulties 
in repeating cell administration due to invasiveness of the 
method when a single administration does not result in 
the desired level of improvement. Insufficient graft sur-
vival after transplantation has been shown in a model 
of Parkinson’s disease (PD) and in the brains of normal 
rodents (6,14,15). In the study of Camp et al. (11), failure 
of mesenchymal stem cells (MSCs) to prevent nigrostri-
atal dopamine depletion and behavioral deficits in the rat 
6-hydroxydopamine (6-OHDA) model of PD was at least 
partially ascribed to the tissue damage resulting from the 
surgical transplantation procedure.
Intravenous (IV) application of cells is another method 
frequently used for cell-based therapies of central nervous 
system (CNS) disorders. Despite its noninvasiveness and 
therapeutic successes shown in different models of CNS 
diseases, such as experimental autoimmune encephalomy-
elitis (EAE), ischemia, traumatic brain injury, and amyo-
trophic lateral sclerosis (ALS) (10,40,73), IV delivery is 
associated with systemic distribution and homing of cells 
to peripheral organs (44,56,65), pulmonary microvascula-
ture entrapment, and lack of significant cell engraftment 
in the brain parenchyma (32,58,72). Moreover, a recent 
study by yang et al. showed that intra-arterial (IA) delivery 
is not superior to IV delivery of autologous bone marrow 
mononuclear cells to the brain in the rat acute ischemic 
stroke model. The number of cells delivered to the isch-
emic area did not significantly differ between the IV and 
IA groups and was below 0.001% of applied cells (78).
Our previously published work demonstrated that non-
invasive intranasal application (INA) of bone marrow-
derived MSCs results in delivery of numerous stem cells 
to different brain areas of healthy rodents and of the rat 
6-OHDA model of PD, including the olfactory bulb (OB), 
cortex, and striatum (20,21). Out of 1 × 106 intranasally 
delivered MSCs, 2.4 × 105 were detected in the brains of 
6-OHDA-lesioned rats 4.5 months after administration 
(20). Similar delivery efficiency of intranasal human 
neural stem/progenitor cells in an intracerebral model of 
glioma was reported by Reitz et al. (59). Besides our pre-
viously published data on INA of MSCs in the 6-OHDA 
model of PD, therapeutically efficient intranasal deliv-
ery of different types of cells (MSCs, T-regulatory cells, 
neural stem/progenitor cells) was successfully shown in 
a variety of disease models [for review, see (12)], such as 
neonatal ischemia (71), stroke (74), 6-OHDA model of 
PD (9), neonatal brain damage (23), EAE model (28,75), 
and intracerebral glioma models (4,59). Thus, INA pro-
vides a more efficient and targeted method for delivering 
cells to the brain than systemic administration. Moreover, 
INA of therapeutic cells helps to avoid problems associ-
ated with surgical transplantation, such as the low survival 
rate of transplanted cells, limitations in cell dosage, and 
the impracticality of repeated surgical administration.
Direct intranasal delivery of therapeutic biological mole-
cules to the CNS has been demonstrated by many laborato-
ries over the last two decades involving rapid extracellular 
delivery along both the olfactory (29) and trigeminal 
(67) neural pathways [see (22,49) for reviews]. Evidence 
supporting the involvement of these neural pathways in 
intranasal delivery of stem cells to the CNS has also been 
discussed (20,21).
MSCs have been proposed for cell-based therapy of 
CNS disorders including PD [for review, see Kitada and 
Dezawa (41)], Alzheimer’s (AD) (46), Huntington’s dis-
ease, stroke, and ALS [for review, see Joyce et al. (37)]. Our 
previous work showed that INA of bone marrow-derived 
MSCs in unilaterally 6-OHDA-lesioned rats led to signifi-
cant improvement of motor deficits reflected by rotational 
behavior and the stepping test (20). Owing to the poten-
tially higher translational relevance of genetic models of 
PD, such as the human A30P mutant SNCA (synuclein, 
a) gene under the control of a human THy1 (thymus cell 
antigen 1, q) promoter [(Thy1)-h[A30P] aSyn] transgenic 
mice, in the present study, we investigated whether intra-
nasally applied MSCs can reach the brain regions affected 
by aSyn (aSyn) pathology in these mice.
Microglia and brain resident macrophages play a sig-
nificant role in AD pathology, amyloid beta (Ab) clear-
ance, and in inflammatory processes contributing to the 
extent of neurodegeneration. Microglia are capable of 
clearing Ab plaques via phagocytosis (48,62,68). This 
process is enhanced by vaccination against Ab (5,42,54). 
Moreover, impaired Ab plaque clearance by mononuclear 
phagocytes has been suggested to be a mechanism for 
amyloid accumulation in the sporadic form of AD (26).
In view of the increasing number of studies suggest-
ing a protective role of microglia and brain resident 
macrophages in AD-like pathology, we further assessed 
intranasal delivery of bone marrow-derived microglia and 
macrophages to the brain in a transgenic mouse model of 
AD and in naive mice.
MATERIALS AND METHODS
Animals
For isolation of macrophages and MSCs, 12- to 18- 
week-old female (n = 2) transgenic C57BL/6-Tg(UBC-
GFP)30Scha/J mice expressing enhanced green fluorescent 
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protein (GFP) under the direction of the human ubiquitin 
C promoter were purchased from Jackson Laboratory 
(Bar Harbor, ME, USA).
For INA of macrophages, 13-month-old female chi-
meric mouse/human amyloid precursor protein (Mo/
HuAPP695swe)/mutant human presenilin 1 (PS1-dE9) [B6.
Cg-Tg(APPswe,PSEN1dE9)85Dbo/J] (Stock No. 005864) 
transgenic mice (n = 3) purchased from Jackson Labs were 
used.
Homozygous (Thy1)-h[A30P] aS female mice (n = 4) 
were generated as described elsewhere (39,55).
Three-month-old male C57BL/6-GFP mice (n = 10) 
from the Centre for Medical Experiments (MEZ) of the 
University of Leipzig were used for isolation of bone 
marrow-derived and culture-differentiated microglia.
Animals were kept under a 12-h dark-to-light cycle, 
with food and water ad libitum.
All procedures were carried out in accordance with the 
guidelines for the care and use of laboratory animals of the 
German Animal Protection Law. The research protocol was 
approved by the Institutional Board of the Ani mal Facility 
of the University Hospital of Tübingen and the local gov-
ernmental authorities (Regierungspräsidium Tübingen, 
permit No. PH2/12, and §4 Abs. 3 Az v. 27.02.13), as well 
as by the Institutional Animal Care and Usage Committee 
(IACUC) of the Landesdirektion Leipzig (Landesdirektion 
Sachsen, Leipzig, permit No. TVV 48/12).
Murine eGFP-MSC Isolation and Culture
Murine MSCs (mMSCs) were isolated from the bone 
marrow of C57BL/6-Tg(UBC-GFP)30Scha/J male animals 
at an age of 6 weeks. Bone marrow cells were flushed out 
of the tibiae and femora under sterile conditions, washed 
with phosphate-buffered saline (PBS; Lonza, Basel, 
Switzerland), counted, and seeded at a density of 1 × 105 
cells per cm2 in standard culture medium (SCM) com-
posed of minimum essential medium with a modification 
(a-MEM; Lonza), 1% penicillin–streptomycin (Lonza), 
and 10% pooled fetal calf serum (FCS; Lonza) to tissue 
culture flasks (Nunc, Roskilde, Denmark). The resulting 
passage (P) 0 cultures were kept at 37°C in humidified 
atmosphere with 5% CO2. Reaching subconfluency, MSCs 
were detached using trypsin-ethylenediaminetetraacetic 
acid (EDTA; Lonza), counted, and plated to fresh tissue 
culture flasks for the subsequent passages at a density of 
1,000 cells per cm2.
Intranasal Delivery of Cells
For delivery of MSCs in aSyn mice and macrophages 
in APP/PS1 mice, intranasal cell or vehicle (PBS) appli-
cation was performed on awake animals. Prior to vehicle 
or cell treatment, aSyn and APP/PS1 mice received intra-
nasally 100 U hyaluronidase (Sigma-Aldrich, St. Louis, 
MO, USA) dissolved in 24 µl sterile PBS to enhance 
migration of cells to the brain (21). Thirty minutes after 
intranasal pretreatment with hyaluronidase, cell suspen-
sions (1 × 106 MSCs or 1.5 × 106 macrophages in 40 µl of 
sterile PBS) or vehicle (PBS) were applied in alternat-
ing 10-µl portions for each nostril. Seven days after INA, 
the animals were sacrificed under ketamine anesthesia 
(75 mg/kg IP; Ketavet, Pfizer, Germany). The brains were 
either frozen at −80°C or processed for FACS analyses as 
described below.
Three-month-old C57BL/6 mice (n = 6) received 1 × 
106 GFP-microglia via INA. After 2 weeks, the animals 
were anesthetized and sacrificed and the organs isolated 
for histological or biochemical analysis.
MSC Characterization
Functional characterization of eGFP-mMSCs involved 
induction of adipogenic, osteogenic, and chondrogenic 
differentiation and flow cytometric surface marker analy-
sis. Briefly, adipogenic and osteogenic differentiation of 
mMSCs was induced at P4 and 41. They were seeded at a 
density of 1,000 cells per cm2 and kept under standard cul-
ture conditions until reaching subconfluency. Subsequently, 
either adipogenic differentiation was induced using “adi-
pogenic medium” composed of SCM supplemented 
with 2 nM dexamethasone, 30 µM indomethacin, 5 µM 
isobuthylmethylxanthine (IBMX), and 10 µg/ml insulin 
(all Sigma Aldrich), or osteogenic differentiation was 
induced using “osteogenic medium” composed of SCM 
with 10 nM dexamethasone, 0.2 mM ascorbic acid, and 
10 mM b-glycerolphosphate (Sigma Aldrich). After 
2 weeks under differentiation conditions, lipid vacuoles in 
adipogenic cultures were stained with Oil Red O (Sigma 
Aldrich) and, after 3 weeks, calcium deposits of osteogenic 
cultures with Alizarin Red S (Sigma Aldrich), respectively. 
For chondrogenic differentiation, 2.5 × 105 mMSCs were 
kept in micromass pellet cultures. Differentiation was 
induced using the hMSC Chondrogenic Differentiation 
BulletKit (Lonza), supplemented with transforming growth 
factor-b3 (TGF-b3; Lonza). After 4 weeks of differentia-
tion, frozen sections of the fixed pellets were performed 
and stained with Safranin O (Lonza).
Flow cytometry analysis of mMSCs was performed 
at P41 using a FACScan instrument (BD Biosciences, 
Heidelberg, Germany) and BD CellQuest Pro software. 
Cells were incubated with phycoerythrin (PE)-labeled 
[anti-cluster of differentiation 4 (CD4), -CD8a, -CD9, 
-CD11b, -CD11c, -CD14, -CD31, -CD43, -CD44, -CD45, 
-CD45R/B220, -CD71, -CD73, -CD86, -CD117, -CD135, 
-CD184, -CD195, -stem cell antigen 1 (SCA-1), -vascular 
endothelial growth factor receptor 2 (VEGFR2) (all BD 
Biosciences), and -CD146 (Bio Legend, Fell, Germany)] or 
unlabeled antibodies [anti-CD29, -CD80, -CD90, -CD105, 
S126 DANIELyAN ET AL.
-CD106, -CD140a, -CD144, -mouse major histocompat-
ibility complex class I (H-2K/H2D), -major histocompat-
ibility complex class II (IA/IE) (all BD Biosciences), 
-CD34 (Abd Serotec, Puchheim, Germany), -CD39 (R&D, 
Wiesbaden, Germany), -CD140b (Epitomics, Burlin-
game, CA, USA), and -CD271 (STEMCELL Technologies, 
Cologne, Germany)] at a concentration of 0.2 µg/105 cells 
for 60 min on ice.
Nonspecific antibody binding was prevented by using 
the Mouse BD Fc Block™ (BD Biosciences) at a con-
centration of 1 µg/106 cells. With regard to the unlabeled 
primary antibodies, PE-labeled secondary antibodies 
(mouse anti-rat Ig, donkey anti-goat IgG, goat anti-rat 
Ig, rat anti-mouse IgG2a+b (BD Biosciences), or goat 
anti-rabbit Ig (Biotrend, Cologne, Germany) were used 
at a concentration of 0.2 µg/105 cells. Dead cells were 
excluded by detection of 7-aminoactinomycin D (Sigma 
Aldrich) uptake. Analysis of percentage of antigen-positive 
cells was performed using FlowJo software (Tree Star, 
Inc., Ashland, OR, USA). The respective isotype-matched 
control was subtracted from all samples to compensate 
unspecific antibody binding.
Differentiation of Bone Marrow Cells Into Macrophages
Whole bone marrow cells from femur and tibia of 12- 
to 18-week-old C57BL/6-Tg(UBC-GFP)30Scha/J female 
(n = 2) mice were flushed out, centrifuged, and then culti-
vated at 3 × 106 cells per 100-mm dish in 10 ml Dulbecco’s 
modified Eagle’s medium (DMEM)/10% FCS/Pen-Strep 
(all PAA, Linz, Austria) supplemented with macrophage-
colony-stimulating factor [M-CSF (R&D); 30 ng/ml]. After 
8 and 9 days, cells were washed and detached with cold 
PBS-EDTA (2 mM) for 30 min at 4°C, washed again, and 
resuspended in PBS (1.5 × 106 cells/40 µl) for the INA.
Flow Cytometry of In Vitro Differentiated Macrophages. 
An aliquot of detached cells was tested for epidermal 
growth factor-like module-containing mucin-like hor-
mone receptor-like 1 mouse homolog (F4/80), CD11b, and 
lymphocyte antigen 6G (Ly6G) expression. The cells were 
stained with CD11b-phycoerythrin-cyanine 7 (PE-Cy7) 
(1:400), Ly6G-PE (1:400), and F4/80-Bio (1:100) fol-
lowed by streptavidin-peridinin-chlorophyll protein-
cyanine 5.5 (PerCPCy5.5) (1:200; all BD Bioscience) for 
20 min at 4°C, then cells were washed with PBS, and 
fluorescence was measured with a FACS-Canto II (BD 
Bioscience). The purity of differentiated eGFP-positive 
macrophages was over 90%.
RNA Isolation and Cell Tracking PCR. GFP-positive 
cells sorted out of the brain hemispheres of animals trans-
planted with eGFP-macrophages were lysed with RLT-
Buffer (Qiagen, Hilden, Germany), and for purification and 
enrichment, the All Prep DNA/RNA Mini Kit (Qiagen) was 
applied according to the manual. Reverse transcription of 
RNA was performed with the Transcriptor High Fidelity 
cDNA Synthesis Kit (Roche, Mannheim, Germany) 
according to the protocol provided. The cDNA was ana-
lyzed with a nested PCR. Primers for PCR 1 were sense 
(5¢-CTTCAGCCGCTACCCCGACC-3¢) and antisense 
(5¢-TCGGCGAGCTGCACGCTGCC-3¢) and generated a 
product of 330 bp. This product was used for the second 
PCR, yielding a 206-bp product with sense (5¢-GTCC 
AGGAGCGCACCATCTTC-3¢) and antisense (5¢-GATGC 
CGTTCTTCTGCTTGTCG-3¢) primers. eGFP-expressing 
MSCs were used as a positive control, and as a negative 
control, an astroglial primary culture (APC) was used. 
The APC was isolated from the whole brains of neonatal 
C57BL/6 mice (Charles River, Sulzfeld, Germany). The 
cells were mechanically dissociated, centrifuged, and cul-
tured in DMEM with 4.5 g/L glucose (Gibco, Carlsbad, 
CA, USA) supplemented with 10% FCS (Biochrom AG, 
Berlin, Germany), 100 µg/ml streptomycin sulfate, 100 units/ 
ml penicillin G, and 100 mM sodium pyruvate (all PAA 
Laboratories) in a humidified 10% CO2 atmosphere at 
37°C. After three passages, at day 15 in culture, the cells 
were frozen until further processing for RNA isolation and 
PCR. Both PCRs were performed with a LightCycler 480 
(Roche) with a primary 5-min denaturation step at 95°C; 
40 cycles with 10-s denaturation at 95°C, 10-s annealing 
at 60°C, and 10-s elongation at 72°C; and a melting curve 
as a final step with 5 s at 95°C and 1 min at 65°C. The PCR 
products were stored at 4°C until analysis on a Qiaxcel 
(Qiagen).
Fluorescence-Activated Cell Sorting
Fluorescence-activated cell sorting (FACS) was per-
formed with a BD FACS Aria II flow cytometer (BD 
Biosciences) using a 100-µm nozzle.
Forward–sideward scatter dot plots were used to exclude 
debris and cell aggregates.
EGFP was excited by a 488-nm laser. Emission filter 
was 530/30 nm. To avoid false-positive events, the brain 
suspension of wild-type (WT) mice intranasally treated 
with vehicle (hyaluronidase in PBS) was employed as a 
negative control, while the cell suspension of cultured 
eGFP-MSCs served as a positive control to set the gates 
for detection of eGFP-positive MSCs after INA.
Differentiation of Bone Marrow Cells Into Microglia
Whole bone marrow (107 cells) was cultivated for 10 
days in 10 ml DMEM/10% FCS in a 60-mm nonadher-
ent Petri dish and differentiation performed as previously 
described (34).
Genomic DNA (gDNA) Isolation. Mice were sacrificed, 
1 ml blood was taken, and mice were perfused with 0.9% 
NaCl (Sigma-Aldrich, Munich, Germany). Organs were 
manually homogenized in peqGOLD TriFast™ (PeqLab, 
Erlangen, Germany), and gDNA was isolated according 
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to the manufacturer’s protocol (PeqLab). Thereafter, 
gDNA was fragmented by passing it through an injec-
tion needle (size 2; B. Braun Melsungen AG, Melsungen, 
Germany) using a 1-ml syringe (Braun). For purification 
and enrichment, the gDNA clean-up XS-kit (Macherey-
Nagel, Dueren, Germany) was applied according to the 
manual.
Cell Tracking qPCR. gDNA of the eGFP-positive trans-
planted cells was tracked in the recipient mice using an 
eGFP-specific primer (U55761.1, sense: 5¢-CATGGTGA 
GCAAGGGCGAGGA; antisense: 5¢-CTTCAGGGTCAG 
CTTGCCGTAGG). 36B4 (ribosomal protein, large, P0; 
Rplp0) was used as a reference (NM_007475.5; sense: 
5¢-CCGTGTGAGGTCACTGTGCCAGCTC; antisense: 
5¢-GCCCAAAGCCTGGAAGAAGGAGGTC). Quantita-
tive PCR was done on the DNA Engine Opticon2 (Biorad, 
Munich, Germany) using Sybr 2x Mastermix (Life 
Technologies GmbH, Darmstadt, Germany), 1x SybrGreen 
(Life Technologies GmbH), and 0.2 µM primer each. Each 
sample was run in triplicate, and a dilution series for the 
standard curve was done with plasmid positive controls 
for absolute quantification. A signal of two molecules 
36B4 counted as one diploid cell. The PCR was run with 
the following cycle conditions: primary denaturation at 
95°C for 3 min, 35 cycles with 30 s at 95°C, 30 s at 60°C, 
and 30 s at 72°C. Fluorescence measurement was done at 
72°C for 36B4 and 86°C for eGFP.
Histologic Analyses
For histologic analyses of eGFP-MSC or -macrophage 
treated APP/PS1 or (Thy1)-h[A30P] aSyn mice, sag-
ittal brain sections (20 µm thick) were fixed in formal-
dehyde (Otto Fischar GmBH & Co. KG, Saarbrucken, 
Germany), washed in PBS, and stained with rabbit poly-
clonal von Willebrand factor (vWF) antibody diluted 1:300 
(DakoCytomation, Glostrup, Denmark) or polyclonal 
ionized calcium-binding adapter molecule-1 (Iba-1) anti-
body diluted 1:500 (Wako, Richmond, VA, USA) or 
mono clonal b amyloid antibody diluted 1:1,000 (6E10, 
Covance, Munich, Germany), or rabbit polyclonal glial 
fibrillary acidic protein (GFAP) antibody diluted 1:500 
(DakoCytomation) for 2 h at room temperature (RT). 
Immunofluorescence staining of phosphorylated aSyn was 
performed using rabbit anti-pS129 (1:500, clone EP1536y, 
Epitomics, Burlingame, CA, USA) and incubated overnight. 
Secondary goat anti-rabbit antibody cyanine 3 (Cy3) 
diluted 1:800 (Dianova, Jackson Immunoresearch, West 
Grove, PA, USA) and Vectashield mounting medium con-
taining 4¢,6-diamidino-2-phenylindole (DAPI; Linaris, 
Wertheim-Bettingen, Germany) were used for visualiza-
tion of antigens and the cell nuclei. Three-dimensional 
imaging of the blood vessels stained with vWF was 
performed using a z-stack of 17 optical sections, 17 µm 
in total thickness using an Olympus IX-81 microscope 
and the CellP software (Olympus Soft Imaging Solutions 
GmbH, Leinfelden-Echterdingen, Germany).
For analyses of brain sections obtained from animals 
treated with eGFP-microglia, C57C57/BL6 mice were 
sacrificed and perfused with 4% paraformaldehyde (PFA; 
Sigma-Aldrich, Munich, Germany). Fixed brains were 
incubated at 4°C for 24 h in 4% PFA followed by incuba-
tion in 30% sucrose (Sigma-Aldrich, Munich, Germany). 
Frozen tissue embedded in Tissue Tek (Sakura, Staufen, 
Germany) was cut into 40-µm sections. The whole brain 
sections were evaluated for accumulation of eGFP-positive 
cells. Immunohistological staining of brain sections with 
Iba-1 antibody (1:700; Wako) was performed. Secondary 
antibody Cy3-conjugated donkey anti-rabbit antibody 
(1:1,000; Dianova) was used.
Statistical Analyses
Analyses of FACS and qPCR data were performed 
by one-way ANOVA with Bonferroni’s test for multiple 
comparisons; p< 0.05 was considered significant. The 
data are presented as mean ± SEM.
RESULTS
Adipo-/Osteo-/Chondrogenic Lineage Differentiation 
Potency of Murine eGFP-MSCs and Surface Marker 
Profile of eGFP-MSCs and eGFP-Macrophages
Prior to INA, surface markers of bone marrow-derived 
eGFP-MSCs were characterized by FACS. Figure 1 shows 
that in vitro, prior to INA, eGFP-MSCs were positive for 
CD9, CD43, CD44, CD71, CD29, CD39, CD105, CD106, 
SCA-1, CD80, CD146, and H2K-H2D and negative for 
CD45, CD14, CD11c, CD11b, CD4, CD8a, CD31, CD34, 
CD45R-B220, CD86, CD73, CD90, CD117, CD135, CD73, 
CD140a and b, CD144, CD184, CD195, CD271, I-A/I-E, 
and VEGF-R2 (data not shown). In vitro differentiation 
experiments of eGFP-MSCs (Fig. 2) demonstrated the 
ability of eGFP-MSCs to differentiate into adipogenic- 
(Fig. 2B), osteogenic- (Fig. 2D), and chondrogenic-like 
(Fig. 2F) cells.
In vitro differentiation of murine eGFP macrophages 
yielded a purity of over 90% as depicted in Figure 2A, 
showing eGFP macrophages stained for F4/80 and CD11b.
INA Delivery of eGFP-Microglia to the  
Brains and Inner Organs of BL/6 Mice
Analysis of biodistribution by PCR showed that in the 
brain, the highest number of cells was found in the OB, 
while hippocampus, cortex, and cerebellum contained 
nearly the same amount of cells; no cells were found in the 
brainstem (Fig. 3A). Among peripheral organs and tissues, 
most of the cells were found in the blood, lungs, and thy-
mus; however, the mean of the cells in all analyzed periph-
eral organs did not exceed 3.4 ×103 cells per organ/tissue 
type, while the maximal number of cells in the brain was 
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Figure 1. FACS analyses of eGFP-MSC surface markers prior to INA. Dot plots show the specific antibody (green) and the respective 
isotype control (red) profiles. FACS, fluorescent-activated cell sorting; eGFP, enhanced green fluorescent protein; MSC, mesenchymal 
stem cell; INA, intranasal application; CD29, cluster of differentiation 29; PE, phycoerythrin; SSC, side scatter; SCA-1, stem cell 
antigen 1; H-2K/H2D, mouse major histocompatibility complex class I.
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2.1 × 104. Comparison of the amount of eGFP-microglia 
detected in the brain to those from peripheral organs/tissues 
revealed significantly higher numbers of cells when com-
pared with thymus, bone marrow, submandibulary lymph 
nodes, liver, kidney, spleen, and heart samples (Fig. 3B). 
The comparison of brain versus blood or lung samples 
revealed a slight, however not significant, difference.
Analysis of brain sections showed that the majority 
of the intranasally transplanted eGFP-microglia were 
found in the corpus callosum, hippocampus, and stria-
tum (Fig. 4A–D) To determine whether transplanted cells 
retain their functional activity, Iba-1 staining was per-
formed, and some cells were found to be positive (arrows 
throughout Fig. 4). Most of the eGFP-microglia showed 
a rounded, ameboid morphology.
Distribution of eGFP-MSCs in the Brains 
of PD Transgenic Mice After INA
The EGFP-MSCs were detected in various brain 
regions of aged (Thy1)-h[A30P] aSyn transgenic mice 
7 days after INA. The most prominent migration was 
seen toward the OB and brainstem (Fig. 5A–D). MSCs 
appeared in close proximity to phosphorylated aSyn 
aggregates (Fig. 5A, C), and astrogliosis was reflected 
by a strong reactivity of glial fibrillary acidic protein 
(GFAP) (Fig. 5B, D). Numerous eGFP-MSCs were closely 
associated with vessels stained with vWF (Fig. 5E), show-
ing, however, the parenchymal localization.
We further quantified the distribution of intranasally 
delivered eGFP-MSCs in brain regions of one hemi-
sphere per animal (n = 4) and isolated these cells by FACS 
for further analysis of eGFP cDNA to confirm their viable 
stage at the point of the brain preparation. Quantitative 
analysis of eGFP-MSC distribution in the brains of 
(Thy1)-h[A30P] aSyn transgenic mice 7 days after INA 
demonstrated that MSCs were present in all investigated 
brain areas. A slightly, however insignificantly, higher 
number of eGFP-MSCs were observed in the brainstem 
and OB (Fig. 6A) in comparison with other brain regions 
(hippocampus, cerebellum, amygdala, and remaining 
brain). The total number of eGFP-MSCs detected per 
brain hemisphere was 834 ± 242 (n = 4). Samples of eGFP-
MSCs isolated from the different brain areas of the cere-
bral hemispheres by FACS were pooled for the analysis 
of eGFP cDNA. Figure 6B shows the presence of eGFP 
cDNA in the brains of (Thy1)-h[A30P] aSyn transgenic 
mice treated intranasally with eGFP-MSCs. Astroglial 
primary culture of postnatal C57BL/6 mice served as a 
negative control, while cultured eGFP-MSCs served as a 
positive control.
Figure 6C–E shows gating for detection of eGFP-
MSCs (eGFP events in the OB and brainstem are shown 
in Fig. 6C and D, and the negative WT control is shown 
in Fig. 6E).
Delivery of eGFP-Macrophages to  
the Brains of APP/PS1 Mice
Intranasal delivery of bone marrow-derived and 
culture-differentiated macrophages to the brain was 
also evaluated using a transgenic mouse model of AD. 
Seven days after INA of cells, the brains were analyzed 
by fluorescence microscopy for the presence of eGFP-
macrophages (Fig. 7).
EGFP-macrophages appeared in the hippocampus 
and occipital cortex closely associated with Ab plaques 
(arrows in Fig. 7A, B). Numerous eGFP-macrophages 
were positive for Ab (arrows in Fig. 7A, B, and F), while 
others located beside the Ab plaques did not reveal Ab 
positivity (arrowheads in Fig. 7A).
Two major populations of eGFP-macrophages were 
identified in the brains of APP/PS1 transgenic mice: 1) 
Iba-1-positive eGFP-macrophages (arrows in Fig. 7E) show-
ing a very similar morphology to Iba-1-positive host micro-
glial cells and 2) Iba-1-negative eGFP-macrophages with 
either rounded large cell bodies (arrowheads in Fig. 7A, E) 
or spindle-like shape (arrowhead in Fig. 7C).
Interestingly, numerous Iba-1-negative eGFP-macro-
phages were seen in the inferior cerebellar peduncle (ICP, 
Fig. 7D) and cerebellum (Fig. 7F) closely associated with 
Ab-positive host tissue. The presence of Ab plaques in 
the cerebellum was recently shown in APP/PS1 transgenic 
mice (50).
DISCUSSION
The present study shows, for the first time, intranasal 
delivery of bone marrow-derived MSCs, macrophages, 
and microglia to the brain in transgenic mouse models of 
PD and AD, respectively.
The rationale for using MSCs as potential candidates 
in cell therapy for PD is based on a variety of studies 
showing and/or suggesting the advantages of MSCs fol-
lowing IV or intracerebral administration in vivo [for 
review, see Kitada and Dezawa (41)].
MSCs are known to possess strong immunomodulatory 
[for review, see yagi et al. (77)], anti-inflammatory, and 
neuroprotective capacities in a variety of neurodegenera-
tive disease models including AD, PD, multiple sclerosis, 
ALS, and traumatic brain injury (10,37,40,46,72). While our 
previous report on intranasal MSCs and numerous others 
using IV versus intracerebral transplantation proved the 
therapeutic efficacy of these cells in the 6-OHDA-induced 
PD model (41), none of the studies in the past investigated 
the delivery and therapeutic potency of intranasally deliv-
ered or surgically transplanted MSCs in genetic models of 
PD. To our knowledge, only the single report of Stemberger 
et al. (66) showed therapeutic potency of intravenously 
applied MSCs in a mouse model of multiple system atro-
phy (MSA). The hallmarks of this model [proteolipid 
protein promotor (PLP)-aSyn transgenic mice], namely, 
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Figure 2. Expression of macrophage-lineage specific markers and trilineage differentiation potential of MSCs. (A) After 9 days 
of differentiation of bone marrow cells, purity of generated macrophages was determined by staining with CD11b and F4/80. In all 
experiments, purity over 90% was achieved. One representative plot is shown. (B–F) MSCs treated with the respective culture media 
show adipogenic, osteogenic, and chondrogenic lineage differentiation in vitro. (B) Adipocyte-like phenotype of MSCs shown by the 
presence of lipid vacuoles stained in red with Red Oil O. (C) Undifferentiated MSCs as control to (B). (D) Alizarin Red-stained cal-
cium deposits in osteogenic differentiated MSCs. (E) Undifferentiated MSCs as control to (D). (F) Chondrogenic differentiated MSCs 
show pellets of mucopolysaccharides stained in red with Safranin O. Scale bar: 100 µm.
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glial cytoplasmic inclusions of aSyn, astrogliosis, and 
microglial activation, provide the link of the MSA model 
to PD and dementia with Lewy bodies pathologies (64). 
IV application of 5 × 105 MSCs in a mouse MSA model 
led to a downregulation of neuroinflammatory cytokines 
and rescued tyrosine hydroxylase (TH)-positive neurons 
in the substantia nigra pars compacta (66) 4 weeks after 
MSC treatment. However, neither behavioral improve- 
ment nor changes in aSyn concentration in midbrain–
brainstem lysates were achieved by IV MSC administration. 
Regrettably, this study did not include the quantification of 
MSCs delivered to the CNS after IV application. A report 
by Camp et al. (11) showed that the survival of MSCs after 
intrastriatal transplantation in unilateral 6-OHDA was 
as low as approximately 8,000 cells out of 4 × 105 MSCs 
applied. The study by Wang et al. demonstrated no survival 
of MSCs in the brain at the endpoint (4 weeks posttrans-
plantation), while very few cells (no exact number avail-
able) were detected in 6-OHDA-lesioned brain 1 week 
after IV delivery of 1 × 107 MSCs (73). Our data show that 
at least 2,078 ± 364 cells can be delivered to the brain of 
(Thy1)-h[A30P] aSyn transgenic mice by a single INA, 
suggesting far better efficacy than that achieved with IV 
administration. Moreover, it is likely that repeated INA of 
Figure 3. Distribution of 1 × 106 INA microglia in the brains and peripheral organs/tissues of 3-month-old C57BL/6 mice. eGFP-pos-
itive microglia were analyzed by qPCR of GFP genomic DNA. As a reference, the single copy gene 36B4 was used. Two copies were 
counted as one diploid cell. The cell number is shown as GFP-positive cells per 1 × 106 total host cells. Distribution of transplanted 
cells is shown in the brain (A) and in the peripheral organs and tissues (B). In the brain, the numbers of cells in hippocampus, cortex, 
cerebellum, and brainstem were compared with those from the OB. In addition, the total brain number of eGFP-positive cells was 
compared to those detected in peripheral organs/tissues (B). *p < 0.05.
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MSCs may achieve and even exceed the number of cells 
that are delivered and survive after surgical transplantation, 
which are extremely limited and may not justify its use. 
Present data showing that a certain population of admin-
istered MSCs, detected in the brainstem, contain phospho-
rylated aSyn hint at their possible ability to participate in 
the clearance of aSyn from the extracellular space, thus 
reducing endocytotic uptake of aSyn by host glia and con-
sequently attenuating glial inflammatory response (7,45).
Microglia and blood-circulating monocytes are con-
sidered to play a prominent role in neuroinflammatory 
response and disease exacerbation in AD. Whether and 
how they affect the formation and clearance of Ab plaques 
is controversial. While depleting perivascular macrophages 
(33) and inhibiting their recruitment to the CNS is associ-
ated with accumulation and reduced clearance of Ab (25), 
the depletion of brain microglia was reported not to affect 
Ab plaque load in two distinct APP transgenic mouse 
models (31).
Our present data show for the first time the successful 
delivery of cells to the brain in a model of AD via INA. 
In particular, bone marrow-derived macrophages were 
detected in different brain areas affected by Ab plaque 
pathology 7 days after INA in APP/PS1 mice. While the 
Ab positivity of eGFP-macrophages may reflect its inter-
nalization, the contribution of allogenic macrophages 
from healthy animals to the overall brain clearance of 
Ab in a transgenic mouse model of AD needs to be fur-
ther explored. The phagocytic activity of monocytes/
macrophages was recently shown to be impaired in AD 
patients (3,26,60,79). Thus, future development of in vitro 
methods to enhance the phagocytic activity of patients’ 
own monocytes may offer a new strategy of administer-
ing reprogrammed monocytes/macrophages to improve 
Ab clearance in AD patients. Since INA allows chronic 
noninvasive application of cells, this delivery method 
could be used to mimic boosting of monocyte production 
and their recruitment to the CNS, without wasteful sys-
temic distribution of in vitro engineered cells (when com-
pared with systemic application) or acute inflammatory 
response of the host tissue after surgical transplantation.
We analyzed the success and the distribution of intra-
nasally applied microglia in a naive mouse to explore 
whether more targeted migration of cells to the brain can 
be achieved in naive animals lacking inflammatory pro-
cesses in the brain that could facilitate cell guidance. Our 
Figure 4. Detection of eGFP-positive microglia in the brains of 3-month-old C57BL/6 mice 2 weeks after INA. Sections stained with 
ionized calcium-binding adapter molecule 1 (Iba-1; red) and 4¢,6-diamidino-2-phenylindole (DAPI) nuclear staining (blue) show the 
presence of eGFP-positive microglia (green) in corpus callosum (A), striatum (B), and hippocampus (C). The majority of cells showed 
negative immunoreactivity to Iba-1 [green cells in (A–C)], while a small population of eGFP-microglia was Iba-1 positive (arrows in 
A–C). (D) Schematic location of eGFP-positive microglia found in the brain slides after INA. Scale bar: 50 µm.
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data show a higher number of cells in the brain of naive 
mice treated intranasally with microglia in comparison to 
the peripheral organs and tissues. Among peripheral tis-
sues/organs, the highest number of eGFP-microglia was 
detected in the blood, suggesting a possible uptake of 
cells directly from the highly vascularized nasal mucosa 
(13,16,35) into the bloodstream. However, the amount 
of cells observed in the blood was as low as 2,475 ± 646 
(0.24% of applied cells).
Another rationale for therapeutic use of autologous 
macrophages/monocytes in AD and various other CNS 
disorders is based on the hypothesis that these cells 
can serve as genetically modified biologic factories for 
producing and delivering growth factors that can improve 
brain cell survival, cognitive function, and Ab clearance 
in AD. One candidate that could be delivered by cells is 
nerve growth factor (NGF) that was shown to impact the 
survival of cholinergic neurons in lesioned rodents and 
aged nonhuman primates (8,69). NGF gene therapy was 
further reported to slow down cognitive decline in the first 
phase I clinical trial without apparent long-term adverse 
effects (70). Among other factors capable of multifaceted 
action in the CNS, erythropoietin (EPO) is a promising 
candidate. Numerous in vivo and in vitro studies have dem-
onstrated its neuroprotective and neurogenesis-enhancing 
features in a variety of brain disease models such as 
Figure 5. Detection of eGFP-MSCs in the brains of 18-month-old aSyn transgenic mice 7 days after INA. Brain sections stained with 
antibodies against either phosphorylated a-synuclein (aSyn) (red in A, C, and E) or glial fibrillary acidic protein (GFAP) (red in B and 
D) contain eGFP-positive MSCs (green and/or yellowish in A–E) located in the close vicinity of aSyn aggregates in the brainstem (A, E) 
or reactive astroglia strongly expressing GFAP in the olfactory bulb (D). MSCs were found in the close proximity of the vessels stained 
with von Willebrand factor (vWF) in different areas of the brain including cortex (red in E). Scale bar:100 µm (A–D), 200 µm (E).
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Figure 6. Distribution of eGFP-MSCs in the brains of 18-month-old aSyn transgenic mice 7 days after INA. The distribution of 
eGFP-MSCs was determined in dissected and suspended brain areas by FACS analysis. (A) eGFP-positive MSCs were sorted [mMSC-
eGFP (transpl.)] and further analyzed for the presence of eGFP cDNA. (B) eGFP cDNA obtained from cultured mMSC-eGFP served as 
a positive control, while brain astroglia-rich primary culture of C57BL/6 neonatal mice served as a negative control [brain culture (neg. 
ctrl.)]. Exemplary dot plots show eGFP-positive MSCs in the OB (C) and brainstem (D) of aSyn transgenic mice. Negative control 
settings using the whole brain cell suspension from the wild-type control mouse treated with the vehicle (PBS) are also shown (E).
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Figure 7. Detection of eGFP-positive murine macrophages in the brains of 13-month-old APP/PS1 mice. Intranasally applied mac-
rophages (green or yellowish cells in A–F) were found in the hippocampus, occipital (OC), and parietal (Par.) cortex, inferior cerebellar 
peduncle (ICP), as well as in the cerebellum (F). Staining of the sections with antibodies against amyloid b (Ab) (red in A, B, and D) 
and Iba-1 (red in C, D, and E) showed the presence of Ab-positive (arrows in A, B, and F) and negative (arrowheads in A), as well as 
Iba-1-positive (arrows in C and E) and negative (arrowheads in C and E) macrophages. Ab-positive macrophages were detected in the 
vicinity of Ab plaques in the hippocampus (A), cortex (B), and cerebellum (F). Scale bar: 100 µm (A, E, and F), 500 µm (B, C, and D). 
APP/PS1 mice, amyloid precursor protein/presenilin transgenic mice.
hypoxia and stroke (17,18,30,36), nontransgenic rodent 
models of AD (1,52), and 6-OHDA model of PD (38,76). 
EPO improves cognition in patients with neuropsychiat-
ric diseases (24) and spatial learning in mice with trans-
genic expression of a constitutively active EPO receptor 
(EPOR) isoform in pyramidal neurons of cortex and hip-
pocampus (61). The improvement of Ab uptake by MSCs 
in vitro (19) and decrease in Ab plaque burden in Tg2576 
mice (47) are concomitant with results showing the decrease 
in EPO and upregulation of its receptor during aging in 
APP/PS1 transgenic mice (51) and increased EPOR in 
hippocampal and cortical astrocytes in patients with mild 
cognitive impairment and sporadic AD (2).
Demonstration of intranasal delivery of MSCs and 
macrophages to the brain in AD and PD transgenic mouse 
models as well as intranasal delivery of microglia to the 
brains of naive mice provide a basis for further investiga-
tions of therapeutic efficacy and a noninvasive intranasal 
method of treatment for AD and PD.
The advantages of intranasal administration of cells in 
comparison with systemic or surgical transplantations can 
be ascribed to 1) its noninvasiveness in comparison with 
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surgical transplantation and, thus, the possibility to use 
multiple applications while avoiding extensive immuno-
logical response associated with surgical transplantation 
and 2) its more targeted and efficacious delivery to the 
brain in comparison with IV and IA administration.
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